|
SMCHD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.24649957022882E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.24950000030589E-08 |
| Normal-vs-Stage2 |
8.67649996294517E-09 |
| Normal-vs-Stage3 |
2.46669995540572E-09 |
| Normal-vs-Stage4 |
1.59209999994747E-06 |
| Stage1-vs-Stage2 |
1.681570E-02 |
| Stage1-vs-Stage3 |
7.666400E-02 |
| Stage1-vs-Stage4 |
3.561600E-01 |
| Stage2-vs-Stage3 |
2.916400E-01 |
| Stage2-vs-Stage4 |
1.976790E-01 |
| Stage3-vs-Stage4 |
6.920200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.42609998757359E-09 |
| Normal-vs-AfricanAmerican |
2.320800E-03 |
| Normal-vs-Asian |
1.644810E-04 |
| Caucasian-vs-AfricanAmerican |
5.586800E-01 |
| Caucasian-vs-Asian |
4.463000E-01 |
| AfricanAmerican-vs-Asian |
9.891400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.78310000098492E-08 |
| Normal-vs-Female |
5.92640048147075E-10 |
| Male-vs-Female |
8.330000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.44179999997485E-06 |
| Normal-vs-Age(41-60Yrs) |
6.84440282228138E-11 |
| Normal-vs-Age(61-80Yrs) |
1.43470000324442E-08 |
| Normal-vs-Age(81-100Yrs) |
7.497000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.745940E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.161500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.287000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.870400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.523600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.595800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.109200E-01 |
| Classical-VS-Follicular |
1.41019999999603E-06 |
| Classical-VS-Other |
2.877800E-01 |
| Classical-VS-Normal |
1.92799999965132E-07 |
| Tall-VS-Follicular |
7.148200E-02 |
| Tall-VS-Other |
6.240000E-01 |
| Tall-VS-Normal |
1.973730E-04 |
| Follicular-VS-Other |
6.171600E-01 |
| Follicular-VS-Normal |
1.18519638547809E-11 |
| Other-VS-Normal |
9.841400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.78389525373746E-11 |
| Normal-vs-N1 |
1.30430000000459E-06 |
| N0-vs-N1 |
4.739600E-01 |
|
|
